Other groups using similar assays to our OX40 assay (7, 14–18) have also found that the majority of recovered COVID-19 patients had detectable responses to pools of spike peptides, but with only a subset of patients having CD4 T cell responses to RBD epitopes. This evidence concerns the gene CD4 and COVID-19.